Terapia hormonal de la menopausia en el año 2021 / Hormone therapy for menopause in 2021

Describe los planteamientos sobre el beneficio de la terapia de reemplazo hormonal en las mujeres en la menopausia y el riesgo de contraer cáncer de mama con el uso prolongado del mismo.

Terapia de reemplazo hormonal después del cáncer de mama: ¿sí, no o quizás? / Hormone replacement therapy after breast cancer: yes, no, or maybe?

Más de nueve millones de sobrevivientes de cáncer de mama en todo el mundo sufren un deterioro en la calidad de vida atribuible a los síntomas de la menopausia relacionados con el déficit de los estrógenos y con los efectos secundarios de la terapia contra el cáncer. La terapia de reemplazo hormonal (TRH) es muy eficaz para controlar estos síntomas en la población general y en las sobrevivientes de cáncer de mama. Sin embargo, la preocupación de la recurrencia del cáncer de mama como resultado del uso de TRH impide que muchos oncólogos utilicen este enfoque en el tratamiento de los síntomas menopáusicos. La evidencia de ensayos aleatorizados, estudios observacionales y meta-nálisis sobre el impacto del uso de TRH en la recurrencia y supervivencia del cáncer de mama sigue siendo controvertida.

More than nine million breast cancer survivors in everyone suffers a deterioration in the quality of life attributable to the symptoms of menopause related to the deficiency of the estrogens and with the side effects of anti-estrogen therapy Cancer. Hormone replacement therapy (HRT) is very effective in controlling these symptoms in the general population and in survivors of breast cancer. However, the concern of recurrence of breast cancer as a result of the use of HRT prevents many oncologists use this approach in the treatment of menopausal symptoms. Evidence from randomized trials, observational studies, and meta-analysis on the impact of the use of HRT on recurrence and Breast cancer survival remains controversial

Hematometra y hematocervix en paciente postmenopáusica: reporte de caso / Hematometry and hematocervix in postmenopausal patient: case repor

El hematometra es la retención de sangre en el útero y comúnmente se presenta en mujeres jóvenes con anomalías mullerianas pero puede aparecer también en mujeres postmenopausicas por causas secundarias como traumas, tumores, terapia de remplazo hormonal, estenosis cervical, entre otras. En esta presentación de caso interesante se describe una mujer postmenopáusica bajo terapia de remplazo hormonal. Dicha mujer inicia con hemorragia uterina anormal por lo que se le realiza ultrasonido evidenciando hematómetra y hematocervix. Como método diagnóstico y terapéutico de la hemorragia postmenopáusica se le realiza histerectomía abdominal en la cual la patología evidencia leiomiomatosis uterina con endometrio secretor

Hematometra is the retention of blood in the uterus and commonly occurs in young women with Mullerian abnormalities but can also appear in postmenopausal women due to secondary causes such as trauma, tumors, hormone replacement therapy, cervical stenosis, among others. In this presentation an interesting case is described a postmenopausal woman under hormone replacement therapy. She said woman began with abnormal uterine bleeding, so an ultrasound was performed showing hematometer and hematocervix. As a method diagnosis and treatment of postmenopausal hemorrhage, abdominal hysterectomy is performed in which the pathology shows uterine leiomyomatosis with secretory endometrium

Terapia Estrogénica y Prevención Cardiovascular Primaria / Estrogen Therapy and Primary Cardiovascular Prevention

Antecedentes La terapia hormonal de la menopausia (THM) corresponde a la administración de hormonas exógenas para el tratamiento de síntomas asociados a climaterio y menopausia. Objetivo Analizar los estudios que dicen relación a THM y riesgo cardiovascular (CV) para entender el concepto de ventana de oportunidad cardiovascular, además analizar la fisiología de los estrógenos en el aparato CV es fundamental para una adecuada comprensión de su rol protector. Método revisión de la literatura disponible en PubMed durante octubre de 2018, utilizando los términos "menopausal hormone therapy'' y ''cardiovascular disease'.Además se revisó base de datos Scielo con los términos "terapia hormonal'', ''menopausia'' y ''cardiovascular''; se escogieron artículos entre 2000 y 2018 con los términos utilizados en el título o resumen. También se realizó búsqueda dirigida de estudios relevantes, guías clínicas, un metanálisis, una revisión sistemática relacionada y las últimas publicaciones de sociedades científicas dela especialidad. Resultados Desde los inicios de la THM se observó en distintos estudios observacionales un papel en la protección CV. Los últimos años se ha ido demostrando a través de diversos estudios aleatorizados, a raíz de las dudas que dejó el WHI de 2002, los beneficios de esta. Conclusión La THM mejora la calidad de vida de las mujeres en climaterio y menopausia. Los estrógenos tienen mejor beneficio sobre enfermedad CV al administrar terapia precozmente luego de la menopausia (ventana de oportunidad) y mantenerla durante un tiempo prolongado de acuerdo a estudios observacionales y aleatorizados. Dado el aumento de la esperanza de vida de la mujer y múltiples FR CV, es que el manejo clínico de la postmenopausia es un relevante problema de salud pública.

SUMMARY Background Menopausal hormone therapy (MHT) is the exogenous administration for climacteric and menopausal treatment. Objective To analyze studies in relation to THM and cardiovascular (CV) risk, to understand the ''cardiovascular window of opportunity'' concept, also, to analyze the physiology of estrogens into cardiovascular system is fundamental for a suitable comprehension of its protective role. Method Review of literature available on PubMed during October 2018, using the terms "menopausal hormone therapy" and "cardiovascular disease." In addition, Scielo database with the terms ''hormone therapy'', ''menopause'' and '' cardiovascular'' was reviewed; Articles were chosen between 2000 and 2018 with the terms used in the title or summary. A directed search of relevant studies, clinical guides, one meta-analysis, one related systematic review and the latest publications of scientific societies of the specialty was also conducted. Results Since beginning of MHT, a role in CV protection has been observed in different observational studies. Recent years have been demonstrated through various randomized studies, following the doubts left by the WHI of 2002, the benefits of MHT. Conclusion MHT improves the quality of life of women in climacteric and menopausal. Estrogen have better benefit on CV disease, by administering early therapy after menopausal and maintaining it for a long time. Given the women increase in life expectancy and multiple CV risk factors, clinical management of postmenopausal is a relevant public health problem.

Evaluación del Tratamiento Homeopático de Mujeres en Climaterio entre los 45 y 60 años con la Menopause Rating Scale (MRS) / Treatment Evaluation Homeopathic Women in Climacteric between 45 and 60 years old with Menopause Rating Scale (MRS)

La terapia hormonal es el tratamiento convencional para contrarrestar síntomas propios del climaterio; sin embargo, algunas mujeres tienen contraindicada esta terapia debido a los efectos adversos que provoca. El objetivo de este estudio fue evaluar la utilidad del tratamiento homeopático durante el climaterio con el uso de la Menopause Rating Scale (MRS) o Escala de Calificación Menopáusica. El estudio incluyó a 31 mujeres, sin problemas cardiacos, sin terapia de reemplazo hormonal y sin antecedentes de cáncer, a quienes se les aplicó el cuestionario de la MRS para obtener un puntuaje antes del tratamiento. Para determinar el tratamiento se utilizó el repertorio electrónico Radar 10.0 para Windows, con el objetivo de repertorizar los síntomas característicos de cada paciente y determinar el medicamento similar. El medicamento fue prescrito en dinamizaciones 30CH, indicando 5 gotas sublinguales cada 8 horas. La evaluación de los pacientes se llevó a cabo cada mes durante tres meses. Se realizó una evaluación final a los tres meses por comparación de puntajes de la escala inicial y final, a través de un análisis estadístico y utilizando la prueba de Wilcoxon. Lachesis trigonocephalus y Pulsatilla nigricans fueron los medicamentos indicados con mayor frecuencia, de acuerdo con los síntomas de cada paciente. La comparación del puntaje, antes y después del tratamiento, evidenció una reducción de síntomas con diferencia estadística, lo cual reflejó una mejoría global del 35%. Esta evidencia sugiere que el tratamiento homeopático beneficia a las mujeres en el climaterio. (AU)

Hormonal therapy is the conventional treatment for counteracting climacteric symptoms; however, this treatment is contraindicated in some women due to the adverse effects that this therapy may cause. The purpose of this study was to evaluate the usefulness of homeopathic therapy during the climacteric using the Menopause Rating Scale (MRS). The study included 31 women, without cardiac problems, history of no cancer or hormone replacement therapy; a MRS scale questionnaire was applied to these women to evaluate each symptom before to treatment. The Radar 10.0 for Windows electronic repertoire was used to repertorize the characteristic symptoms of each patient and determine the similarly. Homeopathic medication was prescribed in 30CH dynamization as 5 sublingual drops every 8 hrs. Patient evaluation took place monthly for 3 months. The evaluation of the results was performed by the comparison of scale scores through a statistical analysis using the Wilcoxon test. Lachesis trigonocephalus and Pulsatilla nigricans were the most frequent treatment indications, according to the symptoms of each patient. At the end of the homeopathic treatment, symptoms reduction was observed with statistical significance in the score, which reflects an overall improvement of 35%. This evidence suggested that homeopathic treatment benefits women in climacteric. (AU)

Medicamentos homeopáticos en el tratamiento del climaterio y la menopausia: una revisión / Homeopathic medicinal products in the treatment of climateric and menopause: a review

RESUMEN Durante el climaterio y la menopausia debido a cambios hormonales pueden presentarse en las mujeres síntomas que afectan la calidad de vida y las relaciones interpersonales. La homeopatía puede ser utilizada como terapia alternativa o complementaria en el manejo de sus síntomas proporcionando múltiples beneficios, escasos efectos secundarios, ahorro de recursos y apertura de una nueva línea para investigar. La bibliografía sobre este tema es insuficiente y se encuentra dispersa lo que dificulta la consulta por parte de los profesionales que la necesitan. Se realizó una revisión bibliográfica con el objetivo de identificar y describir los principales medicamentos homeopáticos que pueden ser utilizados para tratar los síntomas durante el climaterio y la menopausia. Los artículos se identificaron básicamente a través de la búsqueda automatizada en las bases de datos Scielo, PubMed y EBSCO, entre los meses de enero de 2017 a mayo de 2018. Se revisaron aquellos libros y artículos que por su trascendencia fueron considerados como referentes en el tema. Se escogieron 26 referencias bibliográficas que se ajustaban a los objetivos de esta investigación. Fueron identificados y descritos 22 medicamentos homeopáticos susceptibles de ser utilizados en el tratamiento de los síntomas de climaterio y menopausia por lo que puede ser una fuente útil de consulta (AU).

ABSTRACT During the climacteric and menopause, due to hormonal changes, women may present symptoms affecting life quality and interpersonal relations. Homeopathy could be used as an alternative or complementary therapy in the management of those symptoms, providing several benefits, scarce secondary effects, saving resources and opening a new research field. There is not enough bibliography on this topic and it is dispersed, making it difficult for the professional to consult it when it is necessary. A bibliographic review was carried out with the objective of identifying and describing the main homeopathic medicinal products that could be used to treat the symptoms during the climacteric and menopause. The articles were identified mainly through an automated search in Scielo, PubMed and EBSCO databases, in the period from January 2017 and May 2018. Those books and articles considered as referents in the topic because of their transcendence were reviewed. 26 bibliographic references were chosen because they complied with the objective of this research. 20 homeopathic medicinal products capable of being used in the treatment of the climacteric and menopause symptoms were identified and described, being therefore a useful consultation source (AU).

Isoflavones in gynecology

SUMMARY

Terapia de reposição hormonal na menopausa / Hormone replacement therapy in menopause

Embora o estrógeno já esteja disponível para venda há mais de seis décadas, as mulheres ainda permanecem confusas quanto ao risco e aos benefícios da terapia hormonal na menopausa (THM), terapia estrogênica isolada ou associada a progestágenos. A publicação de estudos controlados, randomizados, como o Heart and Estrogen/progestin Replacement Study (HERS) e Women’s Health Initiative (WHI), intensificou essa controvérsia risco/benefício. Milhares de mulheres são tratadas com THM para alívio dos sintomas menopausais, incluindo sintomas vasomotores e sudorese, principal indicação da estrogenoterapia. Outras podem persistir no tratamento na esperança de prevenir doenças crônicas. A manutenção da massa óssea e a prevenção de fraturas são efeitos do estrógeno já bem estabelecidos. Estudos observacionais dos efeitos metabólicos e vasculares do estrógeno sugerem um benefício em potencial na redução do risco de doenças vasculares, mas estudos randomizados e controlados não demonstraram nenhuma evidência de que a terapia hormonal pudesse beneficiar as mulheres com doença vascular previamente instalada ou em mulheres aparentemente saudáveis. O aumento do risco de câncer de mama e doença tromboembólica tem se confirmado nesses estudos. A incidência em números absolutos de efeitos adversos é baixa e o risco individual no primeiro ano de tratamento é muito baixo. Os riscos são cumulativos com o tempo de uso. A relação risco/benefício deve ser individualizada.

Although estrogen has been clinically available for more than six decades, women have been confused by different opinions regarding the risks and benefits of menopausal hormone therapy (HT), estrogen therapy (ET), and estrogen-progestin therapy (EPT). The publication of randomized controlled trials (RCTs), notably, the Heart and Estrogen/progestin Replacement Study (HERS) and Women’s Health Initiative (WHI), has intensified the risk vs. benefit controversy. Millions of women are treated with HT for relief of menopausal symptoms, including vasomotor flushes and sweats, for which estrogen is uniquely and highly effective. Others may continue longer-term treatment in the hope that HT will help to prevent chronic disease. The preservation of bone mass with continuing estrogen therapy and reduction of subsequent risk of fracture is well established. Observational studies of the metabolic and vascular effects of estrogens have suggested a potential benefit in reducing the risk of vascular disease, but recently published randomized controlled trials demonstrated no evidence of benefit in women with established vascular disease or in apparently healthy women. The increased risks of breast cancer and thromboembolic disease have been confirmed in these trials, with evidence of increased risk of stroke. The absolute incidence of an adverse event is low, and the risk of stroke in an individual woman in a single year is very small, but with long-term use, the risks are cumulative over time. The risk-benefit balance needs to be individualized for each woman.

Genistein-induced fluid accumulation in ovariectomised rats' uteri is associated with increased cystic fibrosis transmembrane regulator expression

OBJECTIVE: High genistein doses have been reported to induce fluid accumulation in the uteri of ovariectomised rats, although the mechanism underlying this effect remains unknown. Because genistein binds to the oestrogen receptor and the cystic fibrosis transmembrane regulator mediates uterine fluid secretion, we hypothesised that this genistein effect involves both the oestrogen receptor and cystic fibrosis transmembrane regulator. METHODS: Ovariectomised adult female Sprague-Dawley rats were treated with 25, 50, or 100 mg/kg/day genistein for three consecutive days with and without the ER antagonist ICI 182780. One day after the final drug injection, the animals were humanely sacrificed, and the uteri were removed for histology and cystic fibrosis transmembrane regulator mRNA and protein expression analysis using real-time polymerase chain reaction and Western blotting, respectively. The cystic fibrosis transmembrane regulator protein distribution was analysed visually by immunohistochemistry. RESULTS: The histological analysis revealed an increase in the circumference of the uterine lumen with increasing doses of genistein, which was suggestive of fluid accumulation. Moreover, genistein stimulated a dose-dependent increase in the expression of cystic fibrosis transmembrane regulator protein and mRNA, and high-intensity cystic fibrosis transmembrane regulator immunostaining was observed at the apical membrane of the luminal epithelium following 50 and 100 mg/kg/day genistein treatment. The genistein-induced increase in uterine luminal circumference and cystic fibrosis transmembrane regulator expression was antagonised by treatment with ICI 182780. CONCLUSION: Genistein-induced luminal fluid accumulation in ovariectomised rats' uteri involves the oestrogen receptor and up-regulation of cystic fibrosis transmembrane regulator expression, and these findings reveal the mechanism underlying the effect of this compound on changes in ...

Evaluation of effect of isoflavone on thyroid economy & autoimmunity in oophorectomised women: A randomised, double-blind, placebo-controlled trial.

Background and objectives: The potential of soy isoflavones to interfere with thyroid function has been reported. However, there are limited data regarding their effect on thyroid function and autoimmunity in surgical menopausal women. The present study aimed to evaluate the effect of isoflavones on thyroid function and autoimmunity, menopausal symptoms, serum follicle stimulating hormone (FSH) and estradiol levels in oophorectomised women. Methods: A randomized, double blind, placebo-controlled trial was conducted in 43 oophorectomised women to evaluate the effect of soy isoflavones (75 mg/day for 12 wk) on serum thyroid profile (free T3 , free T4 , TSH, TBG and anti-TPO antibody titres) assessed at baseline, 6 and 12 wk after randomization. Assessment was also done for menopause symptom score (MSS) three weekly, and FSH and estradiol levels at baseline and at study completion. Results: There was a significant alteration in free T 3 levels in the group receiving isoflavones (4.05 ± 0.36, 4.12 ± 0.69 and 3.76 ± 0.55 pmol/l at baseline, 6 and 12 wk, respectively; P=0.02). However, the mean change in various thyroid parameters at 12 wk from baseline was not significantly different between the two groups. MSS was also significantly decreased at 9 and 12 wk from baseline with isoflavones (12.47 ± 8.15, 9.35 ± 5.23 and 9 ± 5.14 at baseline, 9 and 12 wk respectively; P=0.004) with significant improvement in urogenital symptoms compared to placebo. Isoflavones did not significantly affect other parameters during study period. There were no serious adverse events reported and the proportion of patients experiencing adverse events was similar between the two groups. Interpretation and conclusions: Modest reduction in serum free T3 levels in the isoflavone group in the absence of any effect on other thyroid parameters might be considered clinically unimportant.

Effects of isoflavone on the learning and memory of women in menopause: a double-blind placebo-controlled study

Hormone decline is common to all women during aging and, associated with other factors, leads to cognitive impairment. Its replacement enhances cognitive performance, but not all women present a clinical and family or personal history that justifies its use, mainly women with a history of cancer. The aim of this study was to determine whether a daily oral dose of 80 mg of isoflavone extract for 4 months can produce benefits in women with low hormone levels, contributing to improvement in cognitive aspects. The sample comprised 50- to 65-year-old women whose menstruation had ceased at least 1 year before and who had not undergone hormone replacement. The volunteers were allocated to two groups of 19 individuals each, i.e., isoflavone and placebo. There was a weak correlation between menopause duration and low performance in the capacity to manipulate information (central executive). We observed an increase in the capacity to integrate information in the group treated with isoflavone, but no improvement in the capacity to form new memories. We did not observe differences between groups in terms of signs and symptoms suggestive of depression according to the Geriatric Depression Scale. Our results point to a possible beneficial effect of isoflavone on some abilities of the central executive. These effects could also contribute to minimizing the impact of memory impairment. Further research based on controlled clinical trials is necessary to reach consistent conclusions.

Deficiência androgênica na mulher / Androgen deficiency in women

As evidências sugerem que a deficiência androgênica na mulher exibe como principal manifestação clínica a disfunção sexual, especialmente a queda da libido. Entretanto, outros fatores podem também estar implicados na gênese da disfunção sexual, como o relacionamento interpessoal, os estressores sociais, o sedentarismo e o próprio fator masculino. A prevalência da disfunção sexual feminina oscila entre 9 por cento e 43 por cento e recentemente muitos estudos têm mostrado que a reposição com androgênios não só melhora o desempenho sexual, mas também os distúrbios do humor e sintomas vasomotores. Por isso, o profissional de saúde deve sempre incluir no diagnóstico diferencial da disfunção sexual a Síndrome de Deficiência Androgênica, mesmo em mulheres com concentrações séricas normais de estrogênios. O presente artigo tem como objetivo revisar os aspectos práticos da Síndrome de Deficiência Androgênica, enfocando especialmente o diagnóstico e tratamento. Para tanto, nos valemos da análise de 105 artigos publicados em revistas indexadas no PUBMED nos últimos 51 anos (até maio de 2010), incluindo consensos e opiniões de especialistas. Como conclusão, a Síndrome de Deficiência Androgênica na mulher é negligenciada, existindo ainda muitas controvérsias quanto ao seu diagnóstico e terapêutica, especialmente no tocante à escolha do androgênio, a via de administração e o tempo de duração de uso.

The evidences suggest that androgen deficiency in women induces sexual dysfunction as the main clinical manifestation, especially reduction of libido. However, other factors may be involved in the disease genesis, such as interpersonal relationships, social stressors, sedentarism and the partner. Prevalence of sexual problems among women ranges from nine to 43 percent and, recently, many studies have reported that androgens are beneficial not only for the sexual function of women, but for mood disorders and vasomotor symptoms. That is why the physician should include androgen deficiency syndrome as differential diagnosis, even in women with adequate levels of estrogen. Our goal was to present practical aspects of this disease, emphasizing diagnosis and focusing on treatment. This survey covered all the publications indexed in PUBMED in the last 51 years ending May 2010, including consensus and expert opinions; 105 articles were identified. We conclude that the syndrome of androgen deficiency in women is overlooked in clinical practice. There is controversy in literature regarding diagnosis and treatment including choice of drug, route of administration and time of application.

Estetrol: desde un estrógeno fetal hasta el tratamiento de la menopausia / Estetrol: from a fetal estrogen to the treatment of menopause

Estetrol es un esferoide estrogénico sintetizado exclusivamente por el hígado fetal, que traspasa a la circulación materna por la placenta. Descrito por primera vez por Diczfalusy en 1965. Desde esa fecha se han realizado diversas investigaciones preclínicas. En los últimos años, el interés por el estetrol ha aumentado, dado el logro de su síntesis en el laboratorio y la demostración de su buena biodisponibilidad y larga vida media al administrarlo por vía oral a mujeres. Se presenta una revisión de su síntesis, metabolismo y de la información científica existente de sus diferentes efectos en los tejidos estrógeno sensibles en distintos modelos animales.

Estetrol is an estrogenic steroid synthesized exclusively by the fetal liver. It crosses over from the placenta to the maternal circulation. It was first described in 1965 by Diczfalusy and from this date onwards, several preclinical investigations have been carried out. In recent years, the interest for estetrol has been growing due to its laboratory synthesis and the demonstration of its good bioavailability together with its long half life, when administered orally to women. A review of its synthesis, metabolism and existing scientific information on its different effects on estrogen sensitive tissues, in a variety of animal models, is here presented.

Evaluación de la calidad de vida en mujeres de 40 a 59 años mediante la escala MRS (Menopause Rating Scale) / Assessment of quality of life using the Menopause Rating Scale in women aged 40 to 59 years

Background: Climacteric symptoms have a direct relationship with biological and sociocultural factors and significantly impair the quality of life of women. Aim: To assess quality of life and factors affecting it in women aged 40 to 59 years. Material and methods: The Menopause Rating Scale (MRS) was applied to 370 healthy women aged 49 ± 6 years, that accompanied patients to public hospitals in Santiago. Results: Forty four percent of women were postmenopausal and 6 percent used hormone replacement therapy. Half of the group had less than 12 years of formal education and 67 percent had a couple. The mean number of children was 2.8 ± 1.5. Total MRS score was 16.2 ± 8.5. The higher score was given by the psychological domain (7.7 + 4.4), followed by the somatic domain (5.8 ± 3.5). The urogenital domain had the lowest score (2.7 ± 2.9). Eighty percent of women had moderate to severe climacteric symptoms. A logistic regression analysis showed that the postmenopausal condition was the factor that caused the greatest derangement in quality of life, followed by her parity. Formal education had the lowest impact. Conclusions: In this sample of women, menopause significantly deteriorated quality of life and sociocultural factors such as the parity also had an impact.

Depoimentos de mulheres sobre a menopausa e o tratamento de seus sintomas / The opinion of women on menopause and treatment of its symptoms

OBJETIVO: Avaliar a percepção de um grupo de mulheres de Belo Horizonte (MG) sobre a menopausa e seu tratamento. MÉTODOS: Realizou-se análise secundária de dados de estudo populacional de corte transversal com 378 mulheres brasileiras natas, de 40 a 65 anos, com 11 anos ou mais de educação formal. Avaliaram-se os relatos escritos espontaneamente ao final de um questionário sobre sexualidade, entregue por auxiliares de pesquisa e auto-respondido anonimamente. As mulheres foram alocadas em dois grupos: as que escreveram comentários ao final do questionário e as que não escreveram. Compararam-se os grupos em relação às características sociodemográficas e reprodutivas por meio do teste Qui quadrado de Pearson. Os comentários foram transcritos na íntegra para arquivo computadorizado para realizar a análise temática de seu conteúdo, identificando-se e categorizando-se as unidades de significado. RESULTADOS: Aproximadamente um terço das mulheres escreveu comentários (114/378), o que foi significativamente mais freqüente entre as mulheres com menor renda familiar. As principais categorias de análise identificadas foram: a) insegurança/confusão, com as principais idéias referentes a angústia, estresse e dúvidas sobre a menopausa; b) sintomas que provocam sentimentos negativos, como ondas de calor, secura vaginal e alterações de humor; c) terapia de reposição hormonal, medos e sentimentos da falta de convicção por parte dos médicos em prescrevê-la. CONCLUSÃO: Os comentários indicam a necessidade de dar mais atenção aos problemas percebidos no climatério, particularmente direcionada às mulheres menos favorecidas economicamente.

OBJECTIVE: To evaluate the perception of a group of women from Belo Horizonte, Minas Gerais, Brasil, with respect to menopause and its treatment. METHODS: A secondary analysis was performed on data from a population-based, cross sectional study carried out with 378 Brazilian born women between 40 and 65 years of age, with 11 years or more of formal education. Some women added spontaneous comments to the end of the questionnaire on sexuality handed out by research assistants and self-responded anonymously. There were those who provided comments at the end of the questionnaire and those who did not. The groups were compared with respect to sociodemographic and reproductive characteristics using Pearson's chi-square test. Comments were transcribed in their entirety to a computerized file for thematic content analysis, and units of meaning were identified and classified. RESULTS: Approximately one-third of the women (114/378) provided comments. Significantly more women with lower income levels provided comments as compared to those with higher income levels. The principal identified categories of analysis were: a) uncertainty and/or confusion, mainly with regard to anguish, stress and doubts about menopause; b) symptoms that lead to negative feelings, such as hot flushes, vaginal dryness and mood changes; and c) hormone replacement therapy, fears and perception of a lack of conviction in the physicians who prescribe it. CONCLUSION: The comments indicate that more attention must be given to the problems perceived in climacteric women with a special emphasis on those of the lower incomes levels.

Terapia hormonal de reemplazo en prevención cardiovascular: ¿Dónde estamos parados? / Hormone replacement therapy and cardiovascular prevention: Where are we now?

Durante su edad fértil, la mujer sufre una incidencia de enfermedad cardiovascular ateroesclerótica (particularmente infarto de miocardio) significativamente inferior a la del hombre. Este beneficio desaparece progresivamente luego de la menopausia, hasta equilibrarse luego de la sexta década de la vida. Estudios experimentales en modelos animales y humanos sugirieron la existencia de mecanismos fisiológicos por los cuales los estrógenos podrían ser los responsables de esta protección cardiovascular, y análisis retrospectivos de estudios clínicos mostraron que las mujeres climatéricas que habían consumido terapia hormonal de reemplazo (THR) sufrían menos eventos cardiovasculares. Estas observaciones estimularon la ejecución de numerosos ensayos clínicos prospectivos aleatorizados (algunos de gran envergadura) en mujeres climatéricas, destinados a probar la hipótesis de que la THR podría prevenir eventos cardiovasculares graves en esa población. La hipótesis no pudo probarse, ya que en ninguno de esos ensayos la THR fue efectiva, y en algunos casos incluso fue en ciertos aspectos perjudicial. Existen cuestionamientos de orden metodológico que tienen que ver con el diseño de dichos ensayos prospectivos, fundamentalmente la edad de las pacientes incluidas y el momento del inicio de la THR. Existen también razones biológicas que pueden explicar la mencionada contradicción. Una nueva hipótesis, basada asimismo en observaciones experimentales y clínicas, se orienta hacia la posibilidad de que el inicio de la THR en mujeres más jóvenes y más precozmente luego de la menopausia, podría mostrar diferentes resultados.

During their fertile period women suffer significantly less atherosclerotic cardiovascular disease (particularly myocardial infarction) than men. This benefit progressively disappears after menopause, to equalize after the sixth decade of life. Experimental studies in animal and human models demonstrated the existence of physiological mechanisms suggesting that estrogens could be responsible for this cardiovascular protection, and retrospective analysis of clinical studies showed that post menopausal women who had used hormonal replacement therapy (HRT) suffered less cardiovascular events. These observations stimulated the execution of several prospective, randomized clinical trials (some of them with a large number of patients and prolonged follow-up) in post menopausal women, with the aim of proving the hypothesis that HRT could prevent major cardiovascular events. Such hypothesis could not be demonstrated in any of those studies because HRT was not beneficial, and in several cases it was even deleterious in some aspects. Criticism has arisen over some of the methodological aspects of those prospective trials, basically regarding the age of the included patients and the timing of the beginning of HRT. There are also biological reasons that can explain the contradiction. A new hypothesis, also based on experimental and clinical observations, suggests the possibility that beginning HRT in younger women and earlier after menopause could yield different results.